News Release

Comprehensive tumor immunity map opens up immunotherapy to more patients

A more comprehensive method of mapping the immune response to tumors could make immunotherapy an effective option for more people

Peer-Reviewed Publication


Scientists have developed a new way to map the molecules on tumour cells that flag their presence to the immune system, according to a study published today in eLife.

The findings could make commonly used immunotherapy treatments effective for a much larger population of cancer patients.

Some cancer immunotherapy treatments work by targeting short pieces of proteins called peptides that are displayed in the surface of cancer cells. These peptides are presented on the cell surface by human leukocyte antigens (HLAs) of which there are many different types. However, immunotherapy treatment research tends to focus on a small subset of HLAs only. As not all cancer patients produce these HLAs, they are unable to benefit from existing HLA-based immunotherapies.

"Most studies have focused on HLA proteins that are commonly found in the general population," explains co-first author Kenji Murata, a postdoctoral fellow at the Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. "We have developed a new technique that allows the sampling of underrepresented HLA proteins to find peptides or antigens that can induce an antitumour immune response. We can then stimulate the patient's own immune cells with those peptides and give them back to the patient to help treat their cancer."

The team began by isolating white blood cells called T cells from eight patients with melanoma. This patient group spanned 25 different types of HLAs, allowing the team to analyse T cell interactions with more than 800 different antigen peptides. All eight patient samples were positive for at least one of the peptide-HLA combinations. The methods developed here also allowed the team to discover new peptides recognised by the T cells.

Next, the team explored whether the T cells that reacted to the peptides could cause an immune response by measuring the production of an immune-activating molecule called interferon. All except two of the antigens stimulated the T cells to produce interferon as well as stimulate the cells to increase in number. These effects were made more robust by adding to the T cells another type of cell - an artificially engineered antigen-presenting cell (APC) bearing the same antigen, which is a common strategy to stimulate T cells.

In the next stage, the team used the artificial APCs to find the exact immunogenic signal that stimulated the T cells from melanoma patients. They found novel peptide fragments related to two different antigens, called MART1 and NY-ESO1, which are known to contain immunological hotspots. They looked at whether they could engineer T cells to target these novel antigens by taking cells that react against the novel antigens and cloning their T cell receptor (TCR) genes. TCRs are cell-surface proteins that allow T cells to react to antigens. "When we added these cloned TCR genes back into newly isolated T cells, we found that the cells were able to recognise and react to the tumour cells," says co-first author Munehide Nakatsugawa, a former postdoctoral fellow at the Princess Margaret Cancer Centre.

"By querying human melanoma-derived T cells and using novel HLA proteins bearing common tumour antigens, we have been able to discover both new and existing immunologically active antigens in tumours," concludes senior author Naoto Hirano, Senior Scientist at the Princess Margaret Cancer Centre. "Our strategy allows for a more complete examination of the immune response and development of novel cancer vaccines and immunotherapies for a broader group of patients not limited by HLA prevalence or tumour mutation burden."



The paper 'Landscape mapping of shared antigen epitopes and their cognate TCRs of tumour-infiltrating T lymphocytes in melanoma' can be freely accessed online at Contents, including text, figures and data, are free to reuse under a CC BY 4.0 license.

This study will be included in eLife's upcoming Special Issue: 'Discovery and Translation of Cancer Immunology'. To be alerted as new papers are published, follow #eLifeCancerImmunology on Twitter.

Media contact

Emily Packer, Senior Press Officer
01223 855373

About eLife

eLife is a non-profit organisation created by funders and led by researchers. Our mission is to accelerate discovery by operating a platform for research communication that encourages and recognises the most responsible behaviours. We work across three major areas: publishing, technology and research culture. We aim to publish work of the highest standards and importance in all areas of biology and medicine, including Immunology and Inflammation, while exploring creative new ways to improve how research is assessed and published. We also invest in open-source technology innovation to modernise the infrastructure for science publishing and improve online tools for sharing, using and interacting with new results. eLife receives financial support and strategic guidance from the Howard Hughes Medical Institute, the Knut and Alice Wallenberg Foundation, the Max Planck Society and Wellcome. Learn more at

To read the latest Immunology and Inflammation research published in eLife, visit

About the Princess Margaret Cancer Centre

The Princess Margaret Cancer Centre has achieved an international reputation as a global leader in cancer care and one of the top five cancer research centres in the world. It's a member of the University Health Network (UHN), which also includes Toronto General and Toronto Western Hospitals, Toronto Rehabilitation Institute and The Michener Institute for Education at UHN.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.